Open AccessMutation-driven drug development in melanoma
Author(s) -
Keith T. Flaherty,
F. Stephen Hodi,
Boris C. Bastian
Publication year - 2010
Publication title -
current opinion in oncology/current opinion in oncology, with cancerlit
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 1.297
H-Index - 95
eISSN - 1080-8140
pISSN - 1040-8746
DOI - 10.1097/cco.0b013e32833888ee
Subject(s) - medicine , melanoma , clinical trial , drug development , targeted therapy , drug , stromal cell , mutation , cancer , oncology , cancer research , pharmacology , biology , gene , genetics
The identification of mutations in signal transduction pathways that are central in melanoma pathophysiology has provided new therapeutic targets for drug development. The purpose of this review is to define those oncogenes for which there are preclinical data supporting clinical trials and to summarize results from clinical investigations.